ASCO-GU – Opdivo's approval might have scuppered Keynote-123
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
ASCO-GI – confirmation for Bristol’s combo, but is there more?
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.
ASCO-GI – another surprising TIGIT success?
Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.
Merck’s latest move is in bispecifics
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
A new order in BTK inhibition
Imbruvica faces challenges on multiple fronts.
